Bristol Myers Squibb (BMY) Change in Account Payables (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Change in Account Payables for 18 consecutive years, with -$29.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Account Payables fell 323.08% year-over-year to -$29.0 million in Q2 2026; TTM through Jun 2026 was $450.0 million, a 533.8% increase from a year earlier, with the FY2025 full-year figure at -$2.0 million, down 101.09% from the prior year.
• Change in Account Payables was -$29.0 million for Q2 2026 at Bristol Myers Squibb, down from $409.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $517.0 million in Q4 2024 and troughed at -$374.0 million in Q3 2024.
• A 5-year average of $48.3 million and a median of -$3.0 million in 2022 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 713.04% in 2023, down 768.42% in 2023.
• Over 5 years, Change in Account Payables stood at $405.0 million in 2022, then grew by 9.63% to $444.0 million in 2023, then increased by 16.44% to $517.0 million in 2024, then plunged by 117.41% to -$90.0 million in 2025, then soared by 67.78% to -$29.0 million in 2026.
• The last three Change in Account Payables figures came in at -$29.0 million (Q2 2026), $409.0 million (Q1 2026), and -$90.0 million (Q4 2025), per Business Quant data.